Renin-angiotensin-aldosterone system (RAAS) inhibitors are evidence-based treatments for
a number of conditions including hypertension, diabetes mellitus, chronic kidney disease …

Hyperkalaemia (HK) in heart failure and chronic kidney disease patients limits the use of
renin–angiotension–aldosterone system (RAAS) inhibitors, and successful intervention may …

Background Sodium zirconium cyclosilicate, a non-absorbed non-polymer zirconium
silicate, is a new potassium binder for hyperkalemia. A previous report showed that …

Background Pivotal randomized trials demonstrating efficacy, safety and good tolerance, of
two new potassium binders (patiromer and sodium zirconium cyclosilicate) led to their recent …

It is well established that an elevated potassium level (hyperkalemia) is associated with a
risk of adverse events including morbidity, mortality and healthcare system cost …

Patients with chronic kidney disease (CKD) have a high risk of hyperkalemia, which
increases mortality and can lead to renin–angiotensin–aldosterone system inhibitor (RAASi) …

Hyperkalemia is common in clinical practice and can be caused by medications used to treat
cardiovascular diseases, particularly renin–angiotensin–aldosterone system inhibitors …

Hyperkalemia can be a life-threatening disorder, especially for at-risk patients with heart
failure, chronic kidney disease, with diabetes, and patients on certain drugs like renin …

Potassium-Binding Agents for the Clinical Management of Hyperkalemia - PMC Back to Top
Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main …

Hyperkalaemia is a life-threatening condition leading to significant morbidity and mortality. It
is common in heart failure (HF) patients due to the disease itself, which often co-exists with …